Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
22 août 2023 16h43 HE
|
Apellis Pharmaceuticals, Inc.
Internal structural variations were identified in the 19-gauge filter needle included in certain injection kits; Apellis recommends use of kits with the 18-gauge filter needle, which are already in...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 août 2023 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
31 juil. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
Generated total U.S. net product revenues of $89.6 million, including $67.3 million for SYFOVRE® (pegcetacoplan injection) and $22.3 million for EMPAVELI® (pegcetacoplan)SYFOVRE reduced nonsubfoveal...
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
30 juil. 2023 13h00 HE
|
Apellis Pharmaceuticals, Inc.
SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected sham in the GALE long-term extension study Safety profile of SYFOVRE in GALE was consistent with...
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
29 juil. 2023 14h52 HE
|
Apellis Pharmaceuticals, Inc.
No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitisConfirmed seven total events of non-occlusive/occlusive retinal vasculitis since launch; more...
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
24 juil. 2023 09h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
10 juil. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
New 30-month data from the GALE long-term extension study of SYFOVRE® (pegcetacoplan injection) to be presented WALTHAM, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc....
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 juil. 2023 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
07 juin 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 juin 2023 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...